Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sports Cardiology Care in the United States: Can We Fix Fractured Cardiac Care?

JACC. Advances·2026
Same author

Obstructive Hypertrophic Cardiomyopathy in a Symptomatic Professional Athlete Treated With Mavacamten.

JACC. Case reports·2026
Same author

Utility of artificial intelligence electrocardiogram screening tool for hypertrophic cardiomyopathy in an adolescent population.

Annals of pediatric cardiology·2026
Same author

Left Ventricular Myocardial Work Indices and Mechanical Dispersion in an Elite Basketball Athlete Population.

The American journal of cardiology·2026
Same author

Long-Term Real-World Impact of Cardiac Myosin Inhibitors on Diastolic Function in Hypertrophic Cardiomyopathy Patients.

The American journal of cardiology·2026
Same author

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

European heart journal·2026

Related Experiment Video

Updated: May 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dabigatran: a new chapter in anticoagulation.

Shameer Ahmed1, Vadim Levin, Robert Malacoff

  • 1Division of Cardiology, Lehigh Valley Health Network, Allentown, PA 18103, USA.

Cardiovascular & Hematological Agents in Medicinal Chemistry
|April 7, 2012
PubMed
Summary
This summary is machine-generated.

Dabigatran offers a new oral anticoagulant option for preventing strokes in non-valvular atrial fibrillation patients. This review details its mechanism, clinical use, and safety compared to warfarin.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: May 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine

Background:

  • Warfarin has been the standard for anticoagulation for 60 years, but has limitations.
  • Limitations include frequent monitoring and drug/food interactions.
  • Newer oral anticoagulants are sought for improved safety and predictability.

Purpose of the Study:

  • To review dabigatran, a novel oral anticoagulant.
  • To cover its chemical structure, mechanism of action, pharmacokinetics, and clinical data.
  • To discuss its use in preventing stroke in non-valvular atrial fibrillation.

Main Methods:

  • Review of existing literature on dabigatran.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Examination of clinical trial results and adverse event profiles.

Main Results:

  • Dabigatran is a direct thrombin inhibitor, available as dabigatran etexilate.
  • Approved for stroke prevention in non-valvular atrial fibrillation.
  • Demonstrates predictable pharmacokinetics and reduced drug/food interactions compared to warfarin.

Conclusions:

  • Dabigatran presents a significant advancement in oral anticoagulation.
  • Offers an alternative to warfarin with a more predictable profile.
  • Clinical implications and adverse effects are crucial for patient management.